Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : FDA Advisory Committee Votes -3-

09/18/2021 | 03:40am EDT

trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine's benefits outweigh its known risks and determination of the vaccine's efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine's ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer's business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBdk3UkVKtpbxm5mC13yg9cg6g2igAQjFf0ZW3SPG3VZ_n_qD1BnvY-Qrj_ZpXrm0m8GMpAOhk_tKdTKFlAhMf3zOD2gw814ZKSh46Wy0hzjPf9p1lcxbcF5m7ri3sDyDnXHYJsrDB2L1wAasK2-bLwuBR1Ouf3MEs1LMNDxdqr5UcnvLOvn8jcu_JzWJCNDmKDMfvi-dBOTmQjrhAfq_TJME7eOAOaYIf3XImN15CpaBSUHaOg7t0GOgJbgn_8k2QOFfWfg44kScUNtjHS0fjO28qHI0NEppN8gYedBifV0qPxr6AmfAo-TYWSGib-yCy2nEq48ht9PqqClJI0KJ7CrkNZECb0okGT-GmxG-adeDR0DvDs6doS7A9b1P8E4cXbv5rnW0GN81HsSws1ayznpDSAtL80W57QDSVh0Eed7g www.sec.gov and https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBZurvgG1XR3OAvHYXCLX2oDDGr-tZw0dGqjX-R3AJj6Z8wMQd_M5cKq3b-qM9EpJcL1uyTO7OTTRwbRx_JXnaVXsehY8XjLmeMzS-NeyruZvYgaq98ftCwZesfhhHXCxn6wqAYXeuCaRB7zVD4b7DXagGAgygP6LYFP7i2F-eUOzMxBdjty8_l5gz7xumWWVUwLNn6c9q7j2wPzi2mbW_iDqXhXhIAYg3gVnwn6A-R5oMAJKhZ1idbgvRhIQmtHoYKdG4oP4_hcD9giRKW-zYG4FZKXXTF_y3in8AmDkGs0Ses3JEl8mDsUvfLEW67st5baWqld1BVCSRsvaMB9Z2XNw4fF-AL8qQrKtayD-rTKOaOLDvIqlyI1350T9lqOj6PSRw8gUKLnnTHe-9UoxWeG8G3Zw6kxTFlKJlhcAzawO www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBT7-ulHMgf1LCpC-Xa01mr9EqkYyFMpjTuqeEWzZtjWQ-A4rtdGTeEQy-QFRIj6sqWjJ_tGUGGknSFbqcS7i0620z4Ilut4kLMmVUl6YL1dR2WJtRtqaE811vCY2hsDTKKiizify0KKDVI4l_AP_GyYTIuPmNNj77_QJin5Tn2oJzfY2muUH4Y23gfMm4SHo91yUQPTBTfffr5nzTEgQXni8aXZhj3yGKKG2__fNWoa9YTehJvabKIA_5xSYe_IkK3IBUE92JZbuNjij77wC8TY= www.BioNTech.de.

BioNTech Forward-looking Statements

This press release contains "forward-looking statements" of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech's efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations

(MORE TO FOLLOW) Dow Jones Newswires

September 18, 2021 03:40 ET (07:40 GMT)

All news about BIONTECH SE
10/15PFIZER : BioNTech ask EU agency to OK vaccine for kids 5-11
AQ
10/15PFIZER : BioNTech Makes European Medicines Agency Submission of Data Focusing COVID-19 Vac..
MT
10/15BIONTECH : Pfizer Seek European Medicines Agency's Approval for COVID-19 Vaccine for Young..
MT
10/15BIONTECH : Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12..
PU
10/15CSL : Reaffirms Commitment to Manufacture 50 Million Doses of AstraZeneca Vaccine
MT
10/15US to Donate Over 17 Million Doses of Johnson & Johnson's COVID-19 Jab to African Union
MT
10/14MODERNA : U.S. to ship 2.4 million doses of COVID-19 vaccine to Pakistan
RE
10/13MODERNA : FDA scientists' analysis of J&J COVID-19 booster data raises red flags
RE
10/13Merck KGaA's Multiple Sclerosis Treatment Drug Shows Improved Quality Of Life In Study
MT
10/13PFIZER : Ghana Gets 1.3 Million Doses of Pfizer-BioNTech's COVID-19 Jab from US
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 684 M 19 354 M 19 354 M
Net income 2021 8 759 M 10 160 M 10 160 M
Net cash 2021 8 861 M 10 278 M 10 278 M
P/E ratio 2021 6,10x
Yield 2021 -
Capitalization 51 569 M 59 820 M 59 820 M
EV / Sales 2021 2,56x
EV / Sales 2022 1,86x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 213,52 €
Average target price 266,65 €
Spread / Average Target 24,9%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE203.83%59 820
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156
BEIGENE, LTD.38.72%33 452